TacticScaleWhat WuXi AppTec (药明康德) Does & How It Makes Money (603259.SS)
Updated October 2026 · reflects WuXi AppTec's latest reported financials
Chinese contract research and manufacturing partner for drug developers. It earns service fees and contract revenue from drug developers that outsource research, testing, clinical development, and manufacturing work to it.
How WuXi AppTec makes money
It earns service fees and contract revenue from drug developers that outsource research, testing, clinical development, and manufacturing work to it. Its WuXi Chemistry, WuXi Testing, and WuXi Biology segments cover projects from target discovery through commercial supply.
What WuXi AppTec does
WuXi AppTec is a Shanghai-based research and manufacturing services provider founded in 2000. It works for drug developers in China, the United States, Europe, and other markets. It reports three main segments. WuXi Chemistry is an integrated contract research, development, and manufacturing (CRDMO) platform that takes synthetic molecules such as small molecules, oligonucleotides, peptides, and complex conjugates from discovery to commercial production. WuXi Testing offers lab services including toxicology, DMPK, and bioanalysis, along with clinical CRO work. WuXi Biology supports projects from target discovery to candidate selection. Its clinical services cover Phase I to IV development, bioequivalence studies, site management, patient recruitment, site start-up, and academic research organization. Because it offers services across the whole drug development chain, clients can outsource individual projects or entire programs to a single partner, and the company earns revenue from service and manufacturing contracts.
Products & services
- WuXi Chemistry CRDMO services (small molecules, oligonucleotides, peptides, conjugates)
- WuXi Testing laboratory services (toxicology, DMPK, bioanalysis)
- WuXi Biology discovery services
- Clinical CRO services (Phase I-IV, bioequivalence)
- Site management organization and patient recruitment
药明康德是做什么的？
药明康德成立于2000年，总部位于上海，为中国、美国、欧洲及全球其他地区的药企提供研发和生产服务。公司主要分为化学（WuXi Chemistry）、测试（WuXi Testing）和生物学（WuXi Biology）等业务板块。化学板块覆盖小分子、寡核苷酸、多肽及复杂偶联药物，提供从药物发现到商业化生产的一体化CRDMO服务。测试板块提供毒理学、药代动力学（DMPK）、生物分析等实验室服务，以及临床CRO服务。 公司的临床服务包括I至IV期临床开发、生物等效性研究、临床现场管理（SMO）、患者招募和研究中心启动等。凭借覆盖新药研发全链条的服务能力，客户既可以外包单个项目，也可以外包整个研发项目，公司主要通过收取服务费和生产合同收入盈利。
What is WuXi AppTec worth?
On an owner-earnings DCF, WuXi AppTec's most-likely value is about ¥98 versus a recent price near ¥158 (62% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥35) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ Capital-intensive — this business reinvests heavily, so free cash flow runs well below its earnings. Fair value here is built on free cash flow, which understates owner earnings for reinvestment-heavy companies — read it as conservative.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
One company, two listings
WuXi AppTec trades in mainland China and in Hong Kong. Same business, same profits — but the two markets can price it at different multiples, because they have different investors, money and reference points.
| Market | Ticker | Price | P/E |
|---|---|---|---|
| Shanghai (A shares) | 603259.SS | ¥157.85 | 21.4× |
| Hong Kong (H shares) | 2359.HK | HK$207.80 | 25.2× |
As of 12 October 2026. Prices in each listing's own currency. Why one profit can carry two prices: Valuation Is Not a Property of the Company.
Related companies
WuXi Biologics (2269.HK) · Asymchem Laboratories (Tianjin) (002821.SZ)